Keros Therapeutics (NASDAQ:KROS) Coverage Initiated at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report issued on Tuesday, MarketBeat reports. The brokerage issued a buy rating on the stock.

A number of other research analysts also recently commented on the company. Scotiabank began coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price for the company. Bank of America reduced their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Cantor Fitzgerald assumed coverage on Keros Therapeutics in a research report on Thursday, October 24th. They set an “overweight” rating for the company. Finally, Guggenheim initiated coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target on the stock. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $67.17 on Tuesday. The business has a fifty day moving average price of $57.30 and a 200-day moving average price of $51.99. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The company has a market capitalization of $2.52 billion, a PE ratio of -13.09 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The business had revenue of $0.39 million for the quarter. During the same period in the prior year, the firm earned ($1.33) earnings per share. The firm’s revenue was up 4750.0% on a year-over-year basis. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.9 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV grew its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics in the third quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics in the 2nd quarter valued at about $128,000. Finally, Ameritas Investment Partners Inc. increased its holdings in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after buying an additional 324 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.